Jounce Therapeutics, Inc. (JNCE)
| Market Cap | 363.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -101.98M |
| Shares Out | 34.16M |
| EPS (ttm) | -3.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $9.12 |
| Previous Close | $7.76 |
| Change ($) | 1.36 |
| Change (%) | 17.53% |
| Day's Open | 7.74 |
| Day's Range | 7.90 - 9.22 |
| Day's Volume | 1,133,010 |
| 52-Week Range | 2.91 - 10.95 |
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...
Jounce is developing several novel immunotherapies that target T cells and macrophages. I am bearish on the success of Vopratelimab and JTX-8064 and neutral on the prospects of JTX-4014 and JT...
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce's PD-1 inhibitor, JTX-4014 -
- Preclinical data highlight Jounce's approach to identif y potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064 -
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2020 Results - Earnings Call Transcript
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020-
The company announced disappointing news from a phase 2 study.
CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...
These biotechs have a long road ahead, but they just might deliver massive growth.
Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapi...
Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc.
Shares of Gilead Sciences Inc. GILD, +2.28% were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.
– Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody –
Jounce Therapeutics' (JNCE) CEO Rich Murray on Q2 2020 Results - Earnings Call Transcript
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...
- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells -
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2020 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2019 Results - Earnings Call Transcript
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
Jounce Therapeutics: An Attractive Immunotherapy Pick For 2020
Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System
CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...
Is (JNCE) Outperforming Other Medical Stocks This Year?
Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.
As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).
Top Ranked Momentum Stocks to Buy for December 2nd
Healthcare bounced back with an outperformance starting the fourth quarter.
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2019 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 28.89% and 19.48%, respectively, for the quarter ended September 2019.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapi...
CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2019 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019.
Jounce Therapeutics established updated deal with Celgene with the potential to earn up to $530 million in payments based on JTX-8064.
Jounce Therapeutics Inc (NASDAQ: JNCE) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG), the latter of which has agr...
Jounce Therapeutics Inc. (NASDAQ: JNCE) shares jumped on Wednesday after the company announced an update on its strategic collaboration with Celgene Corp.
About JNCE
Jounce Therapeutics, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and J... [Read more...]
| Industry Biotechnology | IPO Date Jan 27, 2017 |
| CEO Richard Murray | Employees 129 |
| Stock Exchange NASDAQ | Ticker Symbol JNCE |
Analyst Forecasts
According to 7 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is 9.88, which is an increase of 8.33% from the latest price.